TL;DR: The FDA classifies bulk drug substances into Category 1 (Positive List) or Category 2 (Negative List) to regulate compounding. While Category 1 substances can be compounded, many commonly discussed peptides, including BPC-157, TB-500, and semaglutide base, are not on the positive lists and face significant regulatory scrutiny, limiting their legal compounding. Regulatory clarity on these lists is paramount for patient safety.
1. Introduction: The FDA's Framework for Compounded Peptides
You might assume all medications undergo the same rigorous FDA approval process before reaching patients. Truth is: a significant distinction exists between FDA-approved drug products and compounded preparations. The U.S. Food and Drug Administration (FDA) plays a critical role in overseeing both, but its approach to compounded medications, particularly peptides, operates under a different framework. This framework is primarily governed by Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Section 503A applies to traditional compounding pharmacies that prepare individualized medications for specific patients based on a prescription. Section 503B governs "outsourcing facilities," which operate under Good Manufacturing Practice (GMP) conditions to produce sterile compounded drugs for hospital systems and other healthcare providers in bulk. For both types of facilities, a core question arises: which "bulk drug substances" can legally be used for compounding? This is where the FDA's Category 1 (Positive List) and Category 2 (Negative List) become critical. These lists dictate which ingredients are permissible, directly impacting the availability and legality of compounded peptides. PeptideDive is committed to providing evidence-based, unbiased regulatory information to help you navigate this complex landscape.
2. What Are Category 1 (Positive List) Peptides for Compounding?
Category 1, often referred to as the "Positive List," comprises bulk drug substances that the FDA has determined can be used in compounding by 503A pharmacies and/or 503B outsourcing facilities. This determination is not made lightly. It stems from a thorough review by the FDA's Pharmacy Compounding Advisory Committee (PCAC), which assesses factors like clinical need, safety data, and the availability of FDA-approved alternatives.
Here's the thing: while the concept of a "Positive List" exists, it's crucial to understand that most commonly discussed research peptides are generally not found on the FDA's official positive lists for compounding. These lists primarily contain substances with a long history of safe use in compounding, often for specific patient needs where an FDA-approved drug is not suitable. For instance, you might find certain amino acids, vitamins, or specific excipients on these lists, which support compounding various formulations.
For a substance to be added to a Category 1 list, it typically requires a formal nomination process, robust scientific evidence demonstrating clinical need, and a comprehensive safety review. This process is designed to ensure that compounded medications are both safe and effective for their intended use. The absence of a peptide from these positive lists does not automatically mean it is illegal to possess, but it significantly restricts its legal compounding by licensed pharmacies.
3. Understanding Category 2 (Negative List) and Substances Removed from Lists
In contrast to the Positive List, Category 2, or the "Negative List," identifies bulk drug substances that cannot be used in compounding. The FDA places substances on this list due to various concerns, including significant safety risks, a lack of clinical need that outweighs potential risks, or if the substance is a component of an FDA-approved drug.
This is where the regulatory status of several popular peptides becomes particularly relevant.
-
Semaglutide Base: In 2024, the FDA made a significant decision regarding semaglutide. The agency clarified that semaglutide base was removed from the 503A bulk drug substance list. Why does this matter? Semaglutide is the active ingredient in FDA-approved drugs like Ozempic and Wegovy. The FDA's stance is that compounding semaglutide from its base form is generally problematic and potentially illegal under federal law. This decision aims to prevent the proliferation of compounded versions that may not meet the same quality and safety standards as the approved products, especially when compounded using non-salt forms.
-
BPC-157 and TB-500: The FDA has also issued warning letters to compounding pharmacies regarding peptides like BPC-157 and TB-500. These letters indicate that the FDA considers BPC-157 and TB-500 to be "unapproved new drugs" when compounded. This classification means they are not on the positive lists for compounding, and pharmacies manufacturing or distributing them risk regulatory action. The rationale behind this often centers on the lack of comprehensive human clinical trial data supporting their safety and efficacy for specific medical conditions, as well as their status as investigational compounds rather than established therapeutic agents. You can learn more about BPC-157's specific applications at /blog/bpc-157-for-gut-health/.
These examples highlight the FDA's commitment to patient safety and its efforts to prevent the compounding of substances for which there isn't sufficient evidence of safety and clinical need, or which could undermine the integrity of approved medications.
4. The FDA's Review Process: From Nomination to Classification
The journey for a bulk drug substance to be classified as Category 1 or Category 2 is extensive and transparent. The Pharmacy Compounding Advisory Committee (PCAC), composed of experts in pharmacy, medicine, and pharmacology, plays a central role.
The process typically begins with a public nomination period, where individuals, healthcare professionals, or organizations can submit substances for evaluation. Each nomination must be supported by scientific evidence addressing several key factors:
- Clinical Need: Is there a legitimate medical need for compounding this substance? Are there FDA-approved alternatives available that would render compounding unnecessary?
- Safety Data: What are the known risks, adverse effects, and potential drug interactions? Is there sufficient data from studies (e.g., from PubMed, ClinicalTrials.gov) to assess its safety profile?
- Effectiveness: Is there evidence to suggest the substance is effective for its intended use when compounded?
- History of Use: What is the substance's history in compounding?
Following nomination, the PCAC reviews the submissions and public comments. They hold public meetings where stakeholders can present their arguments. Based on this comprehensive review, the PCAC makes recommendations to the FDA. The FDA then issues guidance documents, updates its official lists, and, if necessary, sends warning letters to non-compliant entities. This iterative process ensures that the regulatory landscape for compounded medications remains dynamic and responsive to emerging scientific evidence and public health concerns.
5. Navigating the Regulatory Landscape: What Patients and Practitioners Need to Know
For both patients considering compounded peptides and the healthcare practitioners who might prescribe them, understanding the current regulatory status is paramount.
First, always consult the official FDA bulk drug substance lists on FDA.gov. These lists are regularly updated and serve as the definitive source for verifying whether a substance can be legally compounded by a 503A pharmacy or 503B outsourcing facility. If a substance is not on a positive list, or worse, is explicitly listed as Category 2 or has been the subject of an FDA warning letter, it generally cannot be legally compounded.
The implications are significant. Obtaining compounded peptides from unregulated sources carries substantial risks. These products may lack quality control, contain incorrect dosages, be contaminated, or even contain undeclared ingredients. The absence of FDA oversight means there's no guarantee of purity, potency, or safety.
Therefore, it is crucial to consult with healthcare professionals knowledgeable about current FDA regulations and compounding pharmacy practices. They can help you understand the legal and safety implications of any compounded medication. For a broader understanding of peptide legality in the U.S., refer to our guide: /blog/peptide-legality-us/.
6. Future Trends and Updates in Peptide Regulation (2026 Outlook)
The regulatory landscape for peptides is not static; it is continually evolving. The FDA has demonstrated an increased scrutiny of novel peptides, particularly those marketed for "wellness" or "anti-aging" purposes without robust clinical evidence or FDA approval. This trend is likely to continue and intensify as the agency seeks to ensure patient safety and prevent the sale of unproven or potentially harmful substances.
As we look towards 2026 and beyond, expect the FDA to issue more guidance, update its lists, and take enforcement actions where necessary. The agency's commitment to protecting public health means that individuals and healthcare providers must remain vigilant. Continuous monitoring of FDA announcements, official guidance documents, and public meeting summaries is essential for staying informed about the latest updates in peptide regulatory status and compounding eligibility.
Bottom Line
The FDA's Category 1 and 2 lists for bulk drug substances are fundamental to the legal and safe practice of compounding. While the concept of a "Positive List" exists, most widely discussed research peptides, including BPC-157, TB-500, and semaglutide base, are either not on these positive lists or have been specifically targeted by FDA actions, severely limiting their legal compounding. Navigating this complex regulatory environment requires diligence, reliance on official FDA sources, and consultation with informed healthcare professionals to ensure patient safety and compliance.
Medical disclaimer: This content is for educational purposes only and is not medical advice. Consult a healthcare professional before starting any peptide protocol.